TC
ABCL icon

TwinBeech Capital’s AbCellera Biologics ABCL Stock Holding History

TwinBeech Capital’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-122,393
Closed -$791K – 609
2023
Q2 		$791K Buy
+122,393
New +$835K 0.02% 476
2023
Q1 		– Sell
-524,095
Closed -$5.31M – 577
2022
Q4 		$5.31M Buy
524,095
+197,644
+61% +$2.28M 0.1% 246
2022
Q3 		$3.23M Buy
+326,451
New +$3.58M 0.09% 258

Other funds holding ABCL

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $116B AUM 61.47% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
FFVM
Founders Fund VII Management San Francisco, California $2.03M AUM 72.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

TwinBeech Capital's ABCL Position: Q3 2023 in Review

TwinBeech Capital sold out of AbCellera Biologics (ABCL) in Q3 2023, closing a stake of 122,393 shares — an estimated $791K sold.

TwinBeech Capital first reported a position in ABCL in Q3 2022 and held it in 3 quarters. The position peaked at $5.31M in Q4 2022. 138 funds tracked by Wall St. Rank hold ABCL as of Q3 2023.

  • TwinBeech Capital reported no remaining AbCellera Biologics position as of Q3 2023 after selling out during the quarter.
  • TwinBeech Capital sold 122,393 AbCellera Biologics shares in Q3 2023, an estimated $791K.
  • TwinBeech Capital first reported a position in AbCellera Biologics in Q3 2022 and held it in 3 quarters.
  • TwinBeech Capital's AbCellera Biologics position peaked at $5.31M in Q4 2022.
  • 138 funds tracked by Wall St. Rank held AbCellera Biologics as of Q3 2023.

Based on TwinBeech Capital's 13F filing for Q3 2023, filed 14 Nov 2023.